NASDAQ:BNTX

Biontech Se Sponsored Adr Stock News

etoro logo Buy BNTX
*Your capital is at risk
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
While people in this country aren't rushing in masses to get updated COVID booster vaccines, take-up has been encouraging. Many are worried about an apparent resurgence in the affliction.
In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.
A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer.
Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.
Germany's BioNtech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.
Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months thr
The updated booster shots arrive as new coronavirus variants circulate.

US FDA authorizes updated COVID vaccines

01:56pm, Monday, 11'th Sep 2023
The U.S. health regulator on Monday authorized updated COVID-19 vaccines that closely match the Omicron variants that are circulating, starting the process to deploy the shots this month.

3 Stocks to Buy For the COVID Resurgence

08:44am, Thursday, 07'th Sep 2023
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting
An updated Covid-19 vaccine made by Pfizer Inc (NYSE:PFE) and BioNTech has been approved by the UK medical regulator, amid a rise in new variants and subvariants of the virus. The new Pfizer-BioNTech
The UK drug regulator said on Tuesday it has approved an updated COVID-19 vaccine by Pfizer and its German partner BioNTech that targets only the Omicron XBB.1.5 subvariant.

BioNTech: Not Just Another Jab In The Arm

05:13pm, Friday, 01'st Sep 2023
BioNTech's Q2 2023 revenues significantly decreased due to declining COVID-19 vaccine sales, but the company holds $15.3B in cash reserves. The company's pipeline includes COVID-19 vaccine development
Pfizer Inc. PFE, -0.25% and BioNTech SE BNTX, +0.58% said Wednesday that its updated COVID-19 vaccine, which is tailored to the new Omicron XBB.1.5 variant has been recommended to receive marketing ap
Drugmakers like Pfizer and Moderna tamped down expectations. Now, cases are increasing.
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fa
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE